Updated meta-analysis of the TP53 Arg72Pro polymorphism and gastric cancer risk

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1787-1791

  Xiang, Bin ^a   Mi, Yuan Yuan ^b   Li, Teng Fei ^a   Liu, Peng Fei ^a  

^a JIANGYIN PEOPLE S HOSPITAL   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Gastric cancer; Meta analysis; P53; Polymorphism

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; META ANALYSIS; RISK FACTOR; STOMACH TUMOR;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872679717     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1787     Document Type: Article

References (42)

1. Bergamaschi D, Gasco M, Hiller L, et al (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402.
2. Birgander R, Själander A, Zhou Z, et al (1996). p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered, 46, 49-54.
3. Capellá G, Pera G, Sala N, et al (2008). DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol, 37, 1316-25.
4. De Feo E, Persiani R, La Greca A, et al (2009). A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res, 675, 60-5.
5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
6. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.
7. Etienne MC, Chazal M, Laurent-Puig P, et al (2002). Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol, 20, 2832-43.
8. Gao L, Nieters A, Brenner H (2009). Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet, 17, 1658-67.
9. Gomes de Souza L, Miranda de Lima J, Dale Cotrim Guerreiro da Silva I, Manoukian Forones N (2009). P53 Arg72Pro polymorphism in gastric cancer patients. J Gastrointest Cancer, 40, 41-5.
10. Hamajima N, Matsuo K, Suzuki T, et al (2002). No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett, 181, 81-5.
11. Hiyama T, Tanaka S, Kitadai Y, et al (2002). p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer, 100, 304-8.
12. Ihsan R, Devi TR, Yadav DS, et al (2011). Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol, 30, 163-71.
13. Katkoori VR, Jia X, Shanmugam C, et al (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res, 15, 2406-16.
14. Ke-Xiang Z, Yu-Min L, Xun L, et al (2012). Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China. Mol Biol Rep, 39, 723-8.
15. Kim N, Cho SI, Lee HS, et al (2010). The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci, 55, 101-10.
16. Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB (2005). Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology, 52, 944-8.
17. Lane DP (1992). Cancer. p53, guardian of the genome. Nature, 358, 15-6.
18. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-31.
19. Li Y, Prives C (2007). Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function. Oncogene, 26, 2220-5.
20. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
21. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A (2010). p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer, 47, 31-4.
22. Mu LN, Lu QY, Yu SZ, et al (2005). Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer, 116, 972-83.
23. Papadakis EN, Dokianakis DN, Spandidos DA (2000). p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun, 3, 389-92.
24. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
25. Pérez-Pérez GI, Bosques-Padilla FJ, Crosatti ML, Tijerina- Menchaca R, Garza-González E (2005). Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol, 40, 56-60.
26. Shen H, Solari A, Wang X, et al (2004). P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep, 11, 1115-20.
27. Shepherd T, Tolbert D, Benedetti J, et al (2002). Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology, 118, 1039-44.
28. Shirai O, Ohmiya N, Taguchi A, et al (2010). P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology, 57, 1595-601.
29. Själander A, Birgander R, Hallmans G, et al (1997). p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-6.
30. Song HR, Kweon SS, Kim HN, et al (2011). p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer, 14, 242-8.
31. Sul J, Yu GP, Lu QY, et al (2006). P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett, 238, 210-23.
32. Thomas M, Kalita A, Labrecque S, et al (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol, 19, 1092-100.
33. Vogelstein B, Lane D, Levine AJ (2002). Surfing the p53 network. Nature, 408, 307-10.
34. Vousden KH, Lane DP (2007). p53 in health and disease. Nat Rev Mol Cell Biol, 8, 275-83.
35. Walker KK, Levine AJ (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA, 93, 15335-40.
36. Wang YC, Lee HS, Chen SK, Chang YY, Chen CY (1999). Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer, 35, 226-30.
37. Wu MT, Chen MC, Wu DC (2004). Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett, 205, 61-8.
38. Xi YG, Ding KY, Su XL, et al (2004). p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis, 25, 2201-6.
39. Yi SY, Lee WJ (2006). A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol, 12, 6536-9.
40. Zhang ZW, Newcomb P, Hollowood A, et al (2003). Ageassociated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res, 9, 2151-6.
41. Zhang ZW, Newcomb P, Hollowood A, et al (2004). A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism. Dig Dis Sci, 49, 254-9.
42. Zhou Y, Li N, Zhuang W, et al (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer, 121, 1481-6.